Quantitative assessment of AD markers using naked eyes: point-of-care testing with paper-based lateral flow immunoassay.

ABSTRACT: Aβ₄₂ is one of the most extensively studied blood and Cerebrospinal fluid (CSF) biomarkers for the diagnosis of symptomatic and prodromal Alzheimer's disease (AD). Because of the heterogeneity and transient nature of Aβ₄₂ oligomers (Aβ₄₂Os), the development of technologies for dynamically detecting changes in the blood or CSF levels of Aβ₄₂ monomers (Aβ₄₂Ms) and Aβ₄₂Os is essential for the accurate diagnosis of AD. The currently commonly used Aβ₄₂ ELISA test kits usually mis-detected the elevated Aβ₄₂Os, leading to incomplete analysis and underestimation of soluble Aβ₄₂, resulting in a comprised performance in AD diagnosis. Herein, we developed a dual-target lateral flow immunoassay (dLFI) us

SUBMITTER: Zhang L 

PROVIDER: S-EPMC8597216 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature